维持性透析患者的癌症筛查:谁、查什么、何时查
该综述指出,通用人群癌症筛查指南不适用于维持性透析患者,因其预期寿命常不足5年,且筛查试验在该人群中的敏感性和特异性可能不同。透析患者接受治愈性治疗的风险增加也可能抵消筛查的生存获益。因此,需采取个体化筛查策略,平衡患者预期寿命、筛查潜在获益与成本及伤害,并特别讨论了透析患者肾细胞癌的特殊情况。
要点
- 通用人群癌症筛查指南不适用于维持性透析患者。
- 透析患者预期寿命常不足5年,筛查试验性能可能不同。
- 需个体化筛查,平衡预期寿命、获益、成本与伤害。
核心结论
- 维持性透析患者的癌症筛查应个体化,平衡预期寿命与筛查的获益、成本及伤害。
主要发现
- 透析患者预期寿命常不足5年,通用筛查推荐不可直接推广。
- 筛查试验在透析患者中的敏感性和特异性可能与通用人群不同。
- 透析患者接受治愈性治疗的风险增加可能抵消筛查的生存获益。
临床怎么用
- 对维持性透析患者不应直接套用通用人群癌症筛查指南。
- 应结合患者预期寿命及筛查潜在获益、成本与伤害制定个体化筛查方案。
- 需特别关注透析患者肾细胞癌的特殊情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer screening guidelines were developed for the general population with the aim of improving health outcomes through early detection. However, these screening recommendations are not generalizable to patients undergoing maintenance dialysis given that their life expectancy is often less than 5 years. In addition, the performance characteristics of screening tests in patients treated by dialysis may not be the same as in the general population, leading to differences in these tests' sensitivity and specificity in detecting cancer. Survival benefits in patients receiving dialysis may also be tempered by increased risks of curative therapies. Given the uncertainties of cancer screening in patients treated by maintenance dialysis, an individualized approach to cancer screening is warranted. This approach should balance the patient's life expectancy and the potential benefits from screening with its potential costs and harm. The special circumstance of renal cell carcinoma in patients treated by dialysis is also discussed.
引用
- Rosner MH. Cancer Screening in Patients Undergoing Maintenance Dialysis: Who, What, and When. Am J Kidney Dis. 2020. PMID: 32305205. doi:10.1053/j.ajkd.2019.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。